🔥🐔 BizChicken 🐔🔥

Companies Similar to Imunon, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Immuno Phage platform

Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immunotherapies for cancer, leveraging platforms such as Immuno Phage and Tumor Microenvironment Activated Biologics.

Tags: bacteriophage, biopharmaceutical, cancer treatment, immunotherapy, monoclonal antibodies

Symbol: SNSE

Recent Price: $0.48

Industry: Biotechnology

CEO: Mr. John K. Celebi M.B.A.

Sector: Healthcare

Employees: 28

Address: 451 D Street, Rockville, MD 02210

Phone: 240 243 8000

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Imunon, Inc.

Imunon, Inc. logo
Market Cap: Lowest
Employees: Lowest

GEN-1, Thermo Dox

Imunon, Inc. is a clinical stage biotechnology company specializing in the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies, focusing on products such as GEN-1 for ovarian cancer and Thermo Dox for various cancer indications.

Tags: Biotechnology, Cancer Treatment, DNA Therapies, Immunotherapy, Vaccines

Symbol: IMNN

Recent Price: $0.82

Industry: Biotechnology

CEO: Dr. Stacy R. Lindborg Ph.D.

Sector: Healthcare

Employees: 33

Address: 997 Lenox Drive, Lawrenceville, NJ 08648

Phone: 609 896 9100

Leadership

  • Stacy R. Lindborg, PhD, President, Chief Executive Officer, and Board Director
  • David Gaiero, Chief Financial Officer
  • Khursheed Anwer, PhD, MBA, Executive Vice President and Chief Science Officer
  • Kristin Longobardi, MBA, Senior Vice President, Strategic Operations
  • Susan Eylward, General Counsel and Corporate Secretary
  • Michael H. Tardugno,
  • Frederick J. Fritz,
  • Donald Braun, PhD,
  • Christine Pellizzari, JD,
  • James E. Dentzer,

Last updated: 2024-12-31

Immuneering Corporation

Immuneering Corporation logo
Market Cap: Lowest
Employees: Low

IMM-1-104 and IMM-6-415

Immuneering Corporation is a biopharmaceutical company focused on developing oncology and neuroscience product candidates, with key products like IMM-1-104 for cancer treatment and IMM-6-415 for solid tumors.

Tags: biopharmaceutical, cancer treatment, drug development, neuroscience, oncology

Symbol: IMRX

Recent Price: $2.25

Industry: Biotechnology

CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Sector: Healthcare

Employees: 66

Address: 245 Main Street, Cambridge, MA 02142

Phone: 617 500 8080

Last updated: 2024-12-31

Immunic, Inc.

Immunic, Inc. logo
Market Cap: Low
Employees: Low

IMU-838

Immunic, Inc. develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, in Phase 2 clinical trials for multiple conditions, including relapsing-remitting multiple sclerosis.

Tags: autoimmune diseases, biopharmaceutical, chronic inflammatory diseases, clinical trials, immunology, therapies

Symbol: IMUX

Recent Price: $1.03

Industry: Biotechnology

CEO: Dr. Daniel Vitt Ph.D.

Sector: Healthcare

Employees: 85

Address: 1200 Avenue of the Americas, New York, NY 10036

Phone: 332 255 9818

Last updated: 2024-12-31

Immunovant, Inc.

Immunovant, Inc. logo
Market Cap: High
Employees: Low

batoclimab

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases, including batoclimab for myasthenia gravis and thyroid eye disease.

Tags: autoimmune diseases, biopharmaceutical, clinical trials, monoclonal antibodies

Symbol: IMVT

Recent Price: $23.88

Industry: Biotechnology

CEO: Dr. Peter Salzmann M.B.A., M.D.

Sector: Healthcare

Employees: 207

Address: 320 West 37th Street, New York, NY 10018

Phone: 917 580 3099

Leadership

  • Pete Salzmann, M.D., MBA, Chief Executive Officer
  • Renee Barnett, MBA, Chief Financial Officer
  • Christine Blodgett, Senior Vice President of Human Resources
  • Andy Deig, Senior Vice President Strategic Finance
  • Michael Geffner M.D., MBA, Chief Medical Officer
  • Julie Kirschling, Senior Vice President, Program and Alliance Management
  • Mark Levine, Chief Legal Officer and Corporate Secretary
  • Bill Macias, M.D., Ph.D., Chief Medical Officer
  • Becky Merlina, Senior Vice President, Global Head of Quality
  • Jody Roth, MS, RAC, PMP, Senior Vice President, Regulatory Affairs
  • Jay S. Stout, PhD, Chief Technology Officer
  • Yan Zheng, Ph.D., Senior Vice President Biostatistics, Programming & Data Management
  • Chandra Adams, Vice President, Associate General Counsel
  • Maria Alba, M.D., Vice President of Clinical Development
  • Farah Ali, Vice President, Clinical Development
  • Jennifer Ashley, Vice President, Associate General Counsel
  • Annetta Beauregard, Vice President, Regulatory Affairs Strategy
  • Harry Berlanga, MSc., VP, CMC & Distribution Quality
  • Ranjit Deshmukh, Ph.D., Vice President of CMC and Technical Operations
  • Scott Forman, MBA, Vice President, Program Management
  • Tom Forman, MBA, Vice President, CMC Project Management
  • Ian Gourley, M.D., Vice President of Clinical Development
  • Thomas Hardy, M.D., Ph.D., Vice President of Drug Safety and Pharmacovigilance
  • Laci Hasenour, Vice President Marketing, Neurology
  • Aileen Ilaria, MBA, Vice President, Clinical Operations – Global Site Management
  • Claudia Jacobs, Ph.D., Vice President of CMC Project Management Operations and Clinical Supply
  • Jonathan Janes, MB, Vice President Clinical Development
  • Ant Kidwell, Vice President of IT and Facilities
  • Chedvi Levin-Sister, Vice President of Finance
  • Launi Masterson, Vice President of Clinical Operations
  • Andy Minke, Vice President Program Management
  • Linda McKerral, Vice President, CMC Analytical Sciences
  • Pooja Mehta, Vice President Drug Substance Tech Transfer
  • Regina Mirra, VP, Regulatory Operational Excellence
  • Jennifer Moseley, Vice President of Clinical Operations
  • Sheetal Patel M.D., MS MBA, Vice President of Clinical Development
  • Cassandra Pauyo, Vice President, Data Management
  • Rod Saponjic Ph.D., MBA, Vice President of Clinical Operations
  • Lauren Schrier, MBA, Vice President of Marketing
  • Frank Torti, M.D., Chairperson of Board of Directors
  • Andrew Fromkin, Member of Board of Directors
  • Douglas Hughes, Member of Board of Directors
  • George Migausky, Member of Board of Directors
  • Atul Pande, M.D., Member of Board of Directors
  • Eric Venker, M.D., Pharm.D., Member of Board of Directors

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

DNA Medicines

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.

Tags: DNA medicines, HPV, biotechnology, cancer, clinical studies, infectious diseases

Symbol: INO

Recent Price: $1.78

Industry: Biotechnology

CEO: Dr. Jacqueline E. Shea Ph.D.

Sector: Healthcare

Employees: 127

Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462

Phone: 267 440 4200

Leadership

  • Jacqueline Shea, Ph.D., President & Chief Executive Officer
  • Peter Kies, Chief Financial Officer
  • Michael Sumner, MB BS, MBA, Chief Medical Officer
  • Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
  • Steve Egge, MBA, Chief Commercial Officer
  • Rob Crotty, J.D., General Counsel and Chief Compliance Officer
  • EJ Brandreth, MBA, Senior Vice President, Quality Assurance
  • Shawn Bridy, MA, MBA, Senior Vice President, Business Development
  • Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
  • Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
  • Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
  • Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
  • Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
  • Roger D. Dansey, M.D., Chief Medical Officer at Seagen
  • Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
  • Jay Shepard, Former President & CEO of Aravive
  • David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
  • Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
  • Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
  • Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
  • Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult

Last updated: 2024-12-31

NexImmune, Inc.

NexImmune, Inc. logo
Market Cap: Lowest
Employees: Lowest

Artificial Immune Modulation

Nex Immune, Inc., a clinical-stage biotechnology company, develops therapies for cancer and immune-mediated diseases using its Artificial Immune Modulation platform. The company is advancing cell therapy candidates including NEXI-001, NEXI-002, and NEXI-003.

Tags: T cell immunotherapies, biotechnology, cancer, cell therapy, immune-mediated diseases, nanoparticle technology

Symbol: NEXI

Recent Price: $0.15

Industry: Biotechnology

CEO: Mr. John Trainer M.B.A.

Sector: Healthcare

Employees: 6

Address: 9119 Gaither Road, Gaithersburg, MD 20877

Phone: 301 825 9810

Leadership

  • Kristi Jones, Chief Executive Officer
  • Mathias Oelke, Ph.D., Chief Scientific Officer
  • Daniel Bednarik Ph.D., Senior Vice President, Molecular Engineering & Protein Design
  • Jack Ragheb, Senior Vice President, Translational Science
  • Tonya Catterton, Vice President, Quality & Compliance
  • Tim Stover, Vice President, Corporate Controller
  • Karen Haslbeck, Head, Human Resources
  • Matt Schiller, Head, Business Development

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation logo
Market Cap: Medium
Employees: Medium

immunoSEQ

Adaptive Biotechnologies Corporation is a commercial-stage company that develops an immune medicine platform for diagnosing and treating various diseases, including COVID-19 and lymphoid cancers.

Tags: COVID-19, cancer, diagnostics, immune medicine, immunosequencing, translational research

Symbol: ADPT

Recent Price: $6.11

Industry: Biotechnology

CEO: Mr. Chad M. Robins M.B.A.

Sector: Healthcare

Employees: 709

Address: 1165 Eastlake Avenue East, Seattle, WA 98109

Phone: 206 659 0067

Last updated: 2024-12-31

Cullinan Oncology, Inc.

Cullinan Oncology, Inc. logo
Market Cap: Medium
Employees: Low

CLN-081

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.

Tags: biopharmaceutical, cancer, clinical trials, immuno-oncology, oncology, therapies

Symbol: CGEM

Recent Price: $12.20

Industry: Biotechnology

CEO: Mr. Nadim Ahmed

Sector: Healthcare

Employees: 85

Address: One Main Street, Cambridge, MA 02142

Phone: 617 410 4650

Last updated: 2024-12-31

Immix Biopharma, Inc.

Immix Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

IMX-110, IMX-111, IMX-120

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.

Tags: Biopharmaceuticals, Clinical Trials, Inflammation, Oncology, Tissue-Specific Therapeutics

Symbol: IMMX

Recent Price: $2.36

Industry: Biotechnology

CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Sector: Healthcare

Employees: 14

Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064

Phone: 310 651 8041

Last updated: 2024-12-31